The purpose of this study is to establish a safe dose of study cells (ATLCAR.CD30.CCR4 and ATLCAR.CD30) to give to patients with CD30+ refractory/relapsed Hodgkin's Lymphoma and Cutaneous T-Cell Lymphoma.
COM_RESEARCHSTUDIES_DETAIL_HEADER_BASIC_CONTACT_4
United States (Nationwide)
Natalie Grover
LCCC - Clinical Trials
Clinical or Medical
Interventional
Cancer (Lymphoma)
24-2197
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
